Benzodiazepines in PTSD: Guideline Contraindication Versus Real-World Prescribing
VA/DoD guidelines advise strongly against benzodiazepines in PTSD, citing worse outcomes and interference with fear extinction. Two patients, at opposite ends of the same drug, show why the guideline and the exam room keep disagreeing.
T.C. is a 26-year-old woman brought to the emergency department six hours after being assaulted on her walk home from a night shift at a hospital lab where she works as a phlebotomist. She is shaking, unable to sit still in the exam chair, and describes her heart "still racing like it hasn't caught up to the fact that it's over." She has no psychiatric history, no prior trauma, and no substance use of any kind — a genuinely clean baseline, confirmed on direct questioning rather than assumed. The ED team's question is narrow and acute: does she get a benzodiazepine tonight, for a level of physiologic arousal that is making it hard for her to participate in her own forensic exam and safety planning.
The guideline literature on this question is specifically about longer-term PTSD management, not about a single dose in the first hours after an assault — the fear-extinction-interference concern is a treatment-course finding, built on data from patients taking benzodiazepines over weeks to months, not a single acute dose given before any exposure-based treatment has even begun. Whether that distinction actually protects a single ED dose from the same theoretical mechanism, or whether it is being used here as a convenient reason to give her something that helps her get through tonight, is the real disagreement. Her sister, waiting just outside the exam room, has already arranged for T.C. to stay with her for the next several nights, which matters to the team's decision precisely because it means whatever is given tonight only has to get her through a single acute window, not substitute for a longer safety plan that does not yet exist.
In the emergency department
She cannot get through the forensic exam like this, and that exam matters both medically and legally. A single low dose of lorazepam tonight is not the chronic-use scenario the guideline is actually warning against — it is acute symptomatic relief so she can participate in her own care in the next two hours, not a treatment plan for her PTSD.
I want to be honest that the fear-extinction evidence was built on sustained dosing, not a single ED dose, so I am not going to claim tonight's dose carries the same risk as six months of daily use. But I also don't think "the data doesn't directly cover this" is the same as "this is proven safe" — it just means we genuinely don't know, and the guideline's caution deserves to carry some weight even here.
If she had any substance-use history, that calculus would shift immediately toward avoiding it altogether — she doesn't, which is part of why I can support a single dose rather than refusing outright.
A single dose tonight, lowest effective, with explicit documentation that this is acute crisis management and not the start of ongoing benzodiazepine therapy. The real safeguard is what happens next: she needs psychiatric follow-up within a week, specifically so that nobody quietly refills this because it worked once.
One dose of lorazepam given in the ED, explicitly framed to T.C. as a one-time measure, with a psychiatric follow-up appointment arranged for within the week.
Agreed unanimously that the single acute dose was reasonable; explicitly NOT agreed that this sets any precedent for ongoing use if her symptoms persist — that decision was deliberately deferred to the follow-up visit rather than made tonight under crisis conditions.
W.D. is a 58-year-old man, a retired machinist with two grown children, who has been on clonazepam 1 mg twice daily for chronic PTSD-related anxiety for eleven years, prescribed originally by a physician who has since left the practice. His chart shows no dose escalation over that period and no evidence of misuse, but he has never been offered trauma-focused psychotherapy and has never had a documented conversation about why the medication was continued year after year rather than reassessed.
He is not in crisis; he is here for a routine medication refill, and the guideline question is entirely different from T.C.'s: not whether a single dose is defensible in an acute moment, but whether eleven years of unexamined maintenance therapy on a drug the VA/DoD guideline specifically advises against is itself the problem, independent of whether the drug is currently "working." The interference-with-fear-extinction concern is exactly the kind of long-term mechanism this patient's history was built to test, and it has never been tested, because he has never been in exposure-based therapy while on the drug to find out whether it was blocking his progress. He mentions, almost as an aside, that he always assumed the medication was simply what a person takes for this and never realized therapy had been an option he was supposed to be offered alongside it.
At the medication-refill visit
Eleven years without ever offering trauma-focused psychotherapy is the actual problem here, not necessarily the clonazepam itself. The guideline's outcomes data on benzodiazepines in PTSD is drawn from exactly this population — long-term maintenance without exposure-based treatment — and he has never had the chance to find out whether he needed the drug at all once real treatment was tried.
I'd slow down before treating eleven stable years as proof the drug is expendable. A taper after a decade on a GABA-A potentiator carries real physiologic risk — rebound anxiety at minimum, seizure risk if done carelessly — and he has no documented misuse or escalation to point to as a reason to move urgently.
This isn't an argument for leaving him on clonazepam forever without ever revisiting it — it's an argument that "start therapy first, taper deliberately alongside it" is safer than treating today's visit as the moment to begin stopping the drug.
Then the plan writes itself without anyone needing to be wrong: refer to trauma-focused psychotherapy now, continue clonazepam unchanged in the meantime, and revisit tapering specifically once he is established in therapy rather than before it. The guideline's concern gets taken seriously without forcing an unsafe taper onto today's visit.
Clonazepam continued unchanged at today's visit; referral placed for trauma-focused psychotherapy, with an explicit plan to revisit tapering once he is engaged in treatment rather than before.
The unresolved piece, left honestly unresolved rather than papered over: nobody at this visit could say with confidence whether eleven years of clonazepam helped him, hurt his long-term trajectory, or was simply neutral — that question will only be answerable once psychotherapy gives him something to compare it against.